TY - JOUR
T1 - Remission of Intermediate Uveitis
T2 - Incidence and Predictive Factors
AU - Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group
AU - Kempen, John H.
AU - Gewaily, Dina Y.
AU - Newcomb, Craig W.
AU - Liesegang, Teresa L.
AU - Kaçmaz, R. Oktay
AU - Levy-Clarke, Grace A.
AU - Nussenblatt, Robert B.
AU - Rosenbaum, James T.
AU - Sen, H. Nida
AU - Suhler, Eric B.
AU - Thorne, Jennifer E.
AU - Foster, C. Stephen
AU - Jabs, Douglas A.
AU - Payal, Abhishek
AU - Fitzgerald, Tonetta D.
AU - Joffe, Marshall M.
AU - Dreger, Kurt A.
AU - Pistilli, Maxwell
AU - Kothari, Srishti
AU - Khacharyan, Naira
AU - Artornsombudh, Pichaporn
AU - Hanish, Asaf
AU - Gangaputra, Sapna S.
AU - Begum, Hosne
AU - Daniel, Ebenezer
AU - Dunn, James P.
AU - Helzlsouer, Kathy J.
AU - Pujari, Siddharth S.
AU - Buchanich, Jeanine
AU - Washington, Terri L.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Purpose: To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission. Design: Retrospective cohort study. Methods: Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at ≥2 visits spanning ≥90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis. Results: Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4–10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42–4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years ago] =3.82; 95% CI, 1.91–7.63), age ≥45 years (HR [vs age <45 years] = 1.79; 95% CI, 1.03–3.11), female sex (HR = 1.61; 95% CI, 1.04–2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23–6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status were not associated with differential incidence. Conclusions: Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission.
AB - Purpose: To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission. Design: Retrospective cohort study. Methods: Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at ≥2 visits spanning ≥90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis. Results: Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4–10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42–4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years ago] =3.82; 95% CI, 1.91–7.63), age ≥45 years (HR [vs age <45 years] = 1.79; 95% CI, 1.03–3.11), female sex (HR = 1.61; 95% CI, 1.04–2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23–6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status were not associated with differential incidence. Conclusions: Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission.
UR - http://www.scopus.com/inward/record.url?scp=85027949372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027949372&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2015.12.034
DO - 10.1016/j.ajo.2015.12.034
M3 - Article
C2 - 26772874
AN - SCOPUS:85027949372
SN - 0002-9394
VL - 164
SP - 110-117.e2
JO - American journal of ophthalmology
JF - American journal of ophthalmology
ER -